GAITHERSBURG, Maryland The Sapien transcatheter aortic valve replacement (TAVR) made by Edwards Lifesciences (Irvine, California) aced its way through a second advisory committee vote earlier this week, the second such outcome in the past year for the device. The circulatory systems advisory committee gave the device's use in inoperable patients a nod last July by a vote of 9-0 that the benefits outweighed the risks, and the vote for patients at high risk for surgery won a convincing 11-0 vote as well, although one panelist abstained from voting.